BCR of prostate cancer is an event of particular concern after treatment of this tumor; BCR usually precedes clinical recurrence and is a predictor of elevated risk of distant metastasis, prostate cancer-specific mortality, and overall mortality [59]. This evidence concerns the gene BCR and neoplasm.